
    
      Adult Rheumatoid Arthritis (RA) participants previously receiving immediate release
      prednisone were enrolled in the trial if they and their physicians both consented. Once
      entered, participant baseline data were captured and they were switched to delayed-release
      prednisone and followed for approximately 12 weeks.
    
  